Skip to main content
. 2019 Jan 29;9:878. doi: 10.1038/s41598-018-37027-2

Figure 5.

Figure 5

Activation of SIRT1 relives RUNX2 and Osteocalcin activation. (a) RUNX2 mRNA significantly decreased via SRT1720 activation and significantly increased via Sirtinol treatment (n = 4–9). (b) Acetylation of RUNX2 promoter region was determined via chromatin immunoprecipitation. RUNX2 promotor acetylation was significantly reduced with SRT1720 activation (n = 3). (c) RUNX2 protein was significantly decreased via SRT1720 activation and significantly increased via Sirtinol treatment (n = 3). (d) OCN activity measured via fluorescence increased in hyperglycaemic conditions compared to osteogenic, with SIRT1 activator attenuating this process and SIRT1 inhibitor Sirtinol increasing OCN fluorescence (n = 4 and 5FoV), OCN mRNA followed a similar pattern, with a decrease in OCN transcripts in SRT1720 activated cells (n = 4–9). *P < 0.05, **P < 0.005, ***P < 0.001. Scale Bars = 10 μm.